A proposed 25% tariff on pharmaceutical imports into the United States could have significant consequences for Indian drug manufacturers, potentially disrupting supply chains and increasing costs for American consumers, according to CNBC TV18.
Speaking from his Mar-a-Lago residence on Tuesday, US President Donald Trump announced plans to impose sectoral tariffs on pharmaceuticals and semiconductor chips, starting at 25% and increasing substantially over the next year. However, Trump clarified that the tariffs would not apply to pharmaceutical companies with manufacturing facilities in the United States, stating, “We want to give them time to come in because, as you know, when they come into the United States and have their plant or factory here, there is no tariff. So we want to give them a little bit of a chance,” as quoted by Financial Post.
Impact on Indian Pharma Exports
India’s pharmaceutical exports to the US reached an estimated $8.73 billion in fiscal 2024, marking a nearly 16% increase from the previous year. These exports accounted for approximately 31% of the industry’s overall international shipments, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil). The proposed tariff hike threatens to shrink Indian drug makers’ profit margins and make generic medicines from India less competitive in the US market.
Industry experts have warned that higher tariffs will likely affect American consumers the most. Sun Pharma MD Dilip Shanghvi previously stated that any tariffs imposed on pharmaceuticals would be passed on to consumers. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), echoed this sentiment, highlighting that India supplies nearly 47% of generic medicines used by American patients, significantly contributing to the country’s healthcare savings.
Trade Negotiations Between India and the US
The announcement of the tariff hikes comes shortly after Indian Prime Minister Narendra Modi met with Trump in Washington last week to discuss trade agreements between the two nations. The two leaders agreed on an ambitious goal of elevating bilateral trade to $500 billion by 2030, more than doubling the current trade volume. Additionally, both countries have committed to finalizing the first phase of the Bilateral Trade Agreement (BTA) by fall 2025 to address existing trade barriers.
Experts suggest that India’s existing tariffs on US-made medicines could become a point of contention in negotiations, with the possibility of their removal preventing retaliatory actions against Indian pharmaceutical exports.
Trump’s Stance on Drug Prices
This is not the first time Trump has targeted the pharmaceutical sector over what he perceives as excessively high drug prices. During his first term in office in 2017, he criticized pharmaceutical companies, accusing them of “getting away with murder.” His latest move indicates a renewed push to reshape the industry’s trade dynamics in favor of domestic production.
As discussions between New Delhi and Washington progress, the Indian pharma industry remains concerned about the long-term implications of the tariffs. With the US being a crucial market for generic drugs, the proposed tariff hikes could reshape global pharmaceutical supply chains and impact drug affordability for millions of Americans.
